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ABSTRACT 
KRAS is one of the most frequently mutated genes across all cancer subtypes. Two 
of the most frequent oncogenic KRAS mutations observed in patients result in glycine to 
aspartic acid substitution at either codon 12 (G12D) or 13 (G13D). Although the 
biochemical differences between these two predominant mutations are not fully 
understood, distinct clinical features of the resulting tumors suggest involvement of 
disparate signaling mechanisms. When we compared the global phosphotyrosine 
proteomic profiles of isogenic colorectal cancer cell lines bearing either G12D or G13D 
KRAS mutations, we observed both shared as well as unique signaling events induced by 
the two KRAS mutations. Remarkably, while the G12D mutation led to an increase in 
membrane proximal and adherens junction signaling, the G13D mutation led to activation 
of signaling molecules such as non-receptor tyrosine kinases, MAPK kinases and 
regulators of metabolic processes. The importance of one of the cell surface molecules, 
MPZL1, which found to be hyperphosphorylated in G12D cells, was confirmed by cellular 
assays as its knockdown led to a decrease in proliferation of G12D but not G13D 
expressing cells. Overall, our study reveals important signaling differences across two 
common KRAS mutations and highlights the utility of our approach to systematically 
dissect the subtle differences between related oncogenic mutants and potentially lead to 
individualized treatments. 
Our findings from studies focusing on two different oncogenic mutations of KRAS 
highlighted the common hyperphosphorylation of TNK2, a non-receptor tyrosine kinase 
that is known to be mutated, overexpressed, or hyperphosphorylated in several cancer 
subtypes. Non-receptor tyrosine kinases represent an important class of signaling 
 iii 
molecules which are involved in driving diverse cellular pathways. Although the large 
majority have been well-studied in terms of their protein binding partners, the interactomes 
of some important non-receptor tyrosine kinases such as TNK2 (also known as activated 
Cdc42-associated kinase 1 or ACK1) have not been systematically investigated. Aberrant 
expression and hyperphosphorylation of TNK2 have been implicated in a number of 
cancers, although the exact proteins and cellular events that mediate phenotypic changes 
downstream of TNK2 are unclear. Biological systems that employ proximity-dependent 
protein labeling methods, such as biotinylation identification (BioID), are being 
increasingly used to map protein-protein interactomes as they provide increased sensitivity 
in finding interacting proteins. Therefore, as an extension of our effort to understand 
oncogenic KRAS signaling and its components, we sought to map the interacting partners 
of TNK2. We also employed Stable Isotope Amino Acid Labeling in Cell Culture (SILAC) 
to quantitatively explore the interactome of TNK2. By performing a controlled 
comparative analysis between full-length TNK2 and its truncated counterpart, we were not 
only able confidently identify site-level biotinylation of previously well-established TNK2 
binders and substrates (NCK1, NCK2, CTTN, STAT3), but also identify of several novel 
TNK2 interactors. We validated TNK2 interaction with one novel interactors, clathrin 
interactor 1 (CLINT1), using immunoblot analysis.  Overall, this work highlights several 
molecules that warrant further experiments to assess their functional significance in TNK2-
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Cancer is the second leading cause of death worldwide (1). At its basis, cancer is a 
genetic disease largely originating from somatic alterations, such as a missense mutations 
and genomic rearrangements. Such alterations that drive cancer often occur in genomic 
regions that code for proto-oncogenes and tumor suppressor genes. These alterations result 
in one or more genes that code for an aberrant protein product that has an increased or 
decreased biochemical activity compared to the product of the wild-type genes. Genomic 
landscape sequencing studies across several cancers have found mutations in RAS genes 
to be the most prevalent feature in all cancer subtypes (2). The RAS superfamily is 
comprised of more than 100 genes that code for small GTP-binding proteins. Among this 
family are three prototypical RAS proteins that are the most relevant when discussing 
cancer mutations: HRAS (Harvey rat sarcoma viral oncogene homolog), KRAS (Kirsten rat 
sarcoma 2 viral oncogene homolog), and NRAS (neuroblastoma RAS viral oncogene 
homolog) (3). These genes have ~88% sequence homology. They differ in their C terminal 
end sequence known as the hypervariable region. Alternate splicing of KRAS within exon 
4 can result in the expression of two different splice variants, KRAS 4A and KRAS 4B, 
though KRAS 4B is the dominant isoform.  
While the pattern of mutational frequency for RAS genes varies across cancer 
subtypes, KRAS is the most frequently mutated across all cancers. Cancer subtypes where 
KRAS mutations are most common include pancreatic ductal adenocarcinoma (~98%), 
colorectal cancer (~45%), and non-small cell lung cancer (~20%) (4,5). In addition to 
differences in mutational frequency across cancers, variation is also observed in the 
frequency of KRAS mutations at specific codons, and the particular substitution mutation 
(2,6). Mutations at codon 12 account for close to 90% of KRAS mutated cancers. 
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Oncogenic KRAS mutations, especially in colorectal cancer tumors, largely result in a 
glycine to aspartic acid substitution at codons 12 (G12D) or 13 (G13D) (Figure 1.1A). 
 To comprehend the basis of the KRAS-driven biological processes, we need to 
understand its canonical biochemical activity. The KRAS gene codes for a small 
membrane-bound GTPase protein that switches structural conformations corresponding to 
an active and inactive state through the binding and hydrolysis of the nucleotide GTP, 
respectively (Figure 1.1B). While this catalytic activity is intrinsic to KRAS itself, the rate 
of GTP exchange and hydrolysis is often regulated through the binding of guanosine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). GEFs 
increase the rate at which KRAS dissociates from GDP in exchange for GTP, while GAPs 
stimulate the intrinsic ability of KRAS to hydrolyze GTP (7). The dynamic binding to 
GAPs/GEFs is orchestrated by upstream signals, such as those from ligand-induced 
activation of receptor tyrosine kinases. In this manner, KRAS serves as a highly regulated 
molecular switch for mediating signal transduction. Activation of KRAS also results in a 
structural conformation that favors protein-protein interaction with other effector binding 
partners of KRAS that allow for diversity in the signaling axes activated downstream of 
KRAS. In addition to the regulation of its catalytic activity, many enzymes are also 
involved to ensure the proper localization of KRAS at the plasma membrane. To form a 
fully functioning protein, KRAS requires processing via several post-translational 
modifications. Like the C-terminal end of most Ras proteins, the last four residues of the 
protein sequence of KRAS harbors a CAAX box that is severs as a recognition motif for 
farnesyltransferases, which catalyze 
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Figure 1.1 Distinct phenotypes observed in codon 12 mutations in KRAS. (A) Schematic 
depicting the domain architecture of KRAS protein along with the location of two mutational 
hotspots. Various domains are indicated as colored ovals and the hypervariable region is shown in 
blue at the C-terminus. Amino acid positions of the domains are marked. (B) Schematic 
summarizing the alteration in activation state of RAS in its GDP and GTP bound state. One of the 
cellular events following RAS activation, namely the physical association with downstream 
effector proteins and activation of downstream pathways, is also depicted. 
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the transfer and attachment of a farnesyl lipid to cysteine residues. Farnesylation of KRAS 
is crucial for mediating its binding and localization to endomembranes such as the surface 
of the endoplasmic reticulum. In addition to farnesylation, other C-terminal features and 
modifications that are important for membrane localization of KRAS include the C-
terminal lysine rich region, carboxymethylation of this cysteine by Isoprenylcysteine 
carboxylmethyltransferase (ICMT1), and proteolytic cleavage of the terminal residues by 
CAAX prenyl protease 2 (RCE1). 
The ability of substitution mutations of KRAS to promote oncogenicity lies in their 
ability to cause aberrant GTPase cycling, which renders the protein in a prolonged active 
state. Several hypotheses have been proposed regarding the exact mechanism behind the 
hyperactivation of mutant KRAS. Since many oncogenic mutations of KRAS are in its 
nucleotide binding pocket, including mutations at codons 12, 13, 61, 117, and 146, it is 
hypothesized that mutations interfere with the protein’s ability to stabilize the nucleotide 
bound to the active site (8,9). Mutations have also been shown to modulate the binding 
affinity of KRAS to GAPs, thus hindering GAP-induced GTPase activity and inactivation 
of KRAS (8). Consequently, these changes to the biochemical activity of KRAS cause 
constitutive activation of KRAS-induced pathways that promote cell proliferation and 
metastasis.  
The regulated activation of KRAS is important for the context-specific activation 
of several downstream pathways. Activated KRAS at the cell surface is capable of 
physically associating with key early signaling proteins, especially kinases and adaptor 
proteins, that initiate various signaling axes that are responsible for promoting cell growth 
and proliferation.  The most notable of these pathways consists of the RAF/MEK/MAPK 
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axis. Activated KRAS binds and contributes to the activation of RAF kinase, which 
subsequently leads to the activation of MAPK (mitogen-activated protein kinase) kinases, 
including MEK (MAP kinase kinase 1) and ERK1/2 (Extracellular regulated kinase 1/2). 
Activation of KRAS also results in signal transduction through the PI3K/AKT pathways 
(3). In this pathway, the binding of the p110 catalytic subunit of phosphoinositide-3-
kinases (PI3Ks) to activated KRAS results in activation of signaling through pathways 
involving the Ser/Thr kinase AKT or PKB, and the transcription factor NF-kB (nuclear 
factor kB). Other important signaling pathways downstream of KRAS are activated by 
binding to Ral guanine nucleotide exchange factors (RalGEFs), phospholipase-C (PLC), 
Ras And Rab Interactor 1 (RIN1), T Cell Lymphoma Invasion And Metastasis 1 (TIAM1), 
Ras association domain-containing protein (RASSF), and other effectors. It is important to 
note that the specific pathway activated downstream of KRAS is determined by several 
factors, including the cell type, the upstream stimulus (growth factors, cytokines, etc), 
regulation by diverse GAPs/GEFs, the binding affinity and specificity of KRAS to its 
downstream effectors, and other context specific factors. 
Mutant forms of KRAS in cancer has been found to drive oncogenic transformation 
through a wide variety of signaling mechanisms. In addition to hyperactivation of the 
canonical pathways induced as part of normal KRAS-mediated signaling, other signaling 
strategies are also employed that sometimes serve as a mechanism to bypass normal 
regulatory pathways. Studies in model systems either harboring endogenous KRAS 
mutations or overexpressing a mutant form of KRAS have identified many such signaling 
mechanisms that are associated with oncogenic KRAS-driven cancers. Various functional 
studies have characterized the importance of Yes1 activated protein 1 (YAP1) and β-
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catenin (CTNNB1) for signaling downstream of KRAS mutations. YAP1 and CTNNB1 
have shown to be overexpressed in pancreatic ductal adenocarcinomas harboring a KRAS 
mutation (10–12). In another set of studies, calmodulin (CaM) was shown to play a crucial 
role in oncogenic KRAS-mediated signaling. By directly binding to KRAS and PI3K, 
calmodulin allows mutant KRAS to activate PI3K/AKT proliferative pathways even in the 
absence of upstream signals from receptor tyrosine kinases (13,14). Finally, another 
important oncogenic mechanism employed by mutant KRAS involves metabolic 
reprogramming with cancer cells and tumors. A plethora of studies have identified mutant 
KRAS-induced rewiring of diverse metabolic pathways (15–19). Several key metabolic 
changes associated with oncogenic KRAS include increased used of glycolytic pathways 
(increased glucose uptake and sensitivity to glucose deprivation) (20), reprogramming of 
glutamine metabolism (21), increased used of autophagy pathways (22,23), and increased 
oxidation of fatty acids (24). 
 The knowledge derived from decades of studies on the biochemical and molecular 
workings of KRAS has been applied and leveraged to the previous and still ongoing efforts 
to develop therapeutics against KRAS-mutated tumors (25). The identification of small 
molecules that selectively bind and inactivate mutant KRAS is a challenging problem, 
forcing studies to search for alternative strategies to indirectly target mutant KRAS (26,27).  
Initial therapeutic efforts were directed towards developing inhibitors of enzymes involved 
in regulating KRAS membrane interaction and subcellular localization. For instance, 
competitive farnesyltransferase inhibitors (FTIs) as well as inhibitors against KRAS 
processing enzymes RCE1 and ICMT1, were developed and tested for their ability to 
disrupt KRAS-driven transformation (28,29). However, the antagonism of tumor growth 
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observed through FTIs was later found to be due to inhibition of other cellular CAAX-
motif harboring proteins that are substrates of these enzymes. The other main strategy has 
been to pharmacologically target signaling molecules found to be essential for sustaining 
the viability of cells and tumors harboring KRAS mutations (30–33). Recent efforts have 
led to the development of a small molecule, ARS853, that can selectively bind and 
inactivate the G12C mutated form of KRAS protein (8,34,35). Many of the recent efforts 
to target mutant KRAS tumors have been informed by a collection of studies that have 
attempted to map the genes whose knockdown or perturbation is synthetically lethal in the 
presence of mutant KRAS. Such studies have employed pools of siRNAs/shRNAs (36–39) 
and more recently CRISPR/Cas9 technologies to screen for such candidates (37,40–42). 
Several notable genes that have been highlighted and later shown to have promising 
therapeutic potential include Polo-like kinase 1 (PLK1) (39,43), TANK-binding kinase 1 
(TBK1) (44), Enhancer of rudimentary homolog (ERH) (45), and Serine/threonine-protein 
kinase 33 (STK33) (46). A recently developed small molecule that modulates protein-
protein interactions between PLKs was recently found to have a therapeutic effect in 
mutant KRAS-expressing tumors (47). 
 Several phenotypic characteristics have been attributed to oncogenic KRAS-
mediated transformation and tumor growth. A key property shared by KRAS-mutated 
tumors is the ability to show resistance to EGFR inhibitors (48–53). Data acquired from 
clinical trials and studies has significantly contributed to our understanding of KRAS 
mutant cancers. Inhibition of EGFR was considered a potentially promising strategy to 
treat colorectal cancer, as it is highly expressed in these tumors. However, retrospective 
analysis of clinical data on cancer patient’s response to treatment with EGFR inhibitors 
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revealed a strong correlation between presence of a KRAS mutation and lack of response 
to these inhibitors. Since the reporting of these findings, many studies have attempted to 
investigate the mechanism of this resistance. The genomic amplification or occurrence of 
activating mutations in other proto-oncogenes in the presence of mutant KRAS, especially 
the genomic region coding for Hepatocyte growth factor receptor (MET), have been 
correlated with increased resistance to clinical inhibitors against EGFR (54–56). However, 
the molecular events and mechanisms that allow KRAS to evade the antagonism to EGFR 
and other RTKs are still unclear. 
Even after decades of studies on biochemical characteristics and functional context 
of KRAS in normal and oncogenic signaling, observations in recent years have revealed 
additional layers of complexity regarding KRAS mutations and tumorigenesis continue to 
unravel. Furthermore, the importance of distinguishing between individual hotspot 
mutations in KRAS is being increasingly appreciated due to accumulating in vitro and 
clinical studies that report observing differences in phenotypic and clinical behavior 
between tumors harboring mutations at codon 12 or codon 13 (57–62). Differences in 
anchorage-independent growth, apoptotic tendency, and metastatic efficiency have been 
reported (63–66). Codon 12 mutations tend to form spheroid shaped colonies that grow in 
size and density over time, while codon 13 mutants form smaller colonies. Codon 12 
mutants also exhibit increased resistance/protection from apoptosis relative to codon 13 
mutants which show higher sensitivity to confluency-dependent apoptosis. In terms of 
clinical presentation, colorectal cancer patients with tumors harboring codon 12 mutations 
show a worse overall survival and prognosis as compared to codon 13 mutated tumors 
(67,68). Furthermore, codon 12 and 13 also exhibit differential degrees of resistant to 
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EGFR inhibitors, with recent clinical studies reporting that G13D mutant patient tumors 
are significantly more responsive to the anti-EGFR monoclonal antibody cetuximab 
compared to codon 12 mutated patient cohorts (58,62).   
The molecular basis of the phenotypic and clinical differences between tumors 
harboring different oncogenic substitution mutations of KRAS is still unclear. The lack of 
understanding regarding the molecular differences in KRAS mutant-specific signaling is, 
in part, owing to a scarcity of studies utilizing controlled biological systems that allow 
direct comparison of individual KRAS mutations. Findings from a heterogeneous 
mutational background that is characteristic of patient samples complicate the 
interpretation of signaling events contributed largely by the activity of mutant KRAS. 
These complications can be avoided by using an isogenic system for different KRAS 
mutants. Several studies have leveraged isogenic systems to study differential signaling 
between wild-type KRAS and mutant KRAS (69–76). However, fewer studies have used 
isogenic systems to explore mutation-specific KRAS signaling (66,70,77). One such 
system that was used previously by Prior et al. profiled the serine and threonine 
phosphoproteome of isogenic SW48 cells harboring either KRAS mutations. This work 
identified proteins and phosphorylation sites showing increased abundance specifically in 
G13D or codon 12 mutants (77). However, the role of tyrosine phosphorylation-mediated 
signaling in oncogenic KRAS-driven cancers has largely been unstudied, as a majority of 
these signaling events are perceived as upstream of KRAS and thus irrelevant to mutant 
KRAS induced signaling events downstream. Although tyrosine phosphorylation accounts 
for only ~1% of total phosphorylation, tyrosine kinases play a disproportionately large role 
in diseases, especially in cancer. Our previous study revealed that activation of serine and 
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threonine kinases by the PI3K-AKT signaling pathway lead to widespread modulation of 
the tyrosine phosphoproteome (78,79). In the present study, we examined mutation-
specific KRAS signaling by characterizing the phosphotyrosine proteome along with total 
proteome downstream of G12D and G13D mutations in the same cell background. Our 
analysis provided insights into changes in phosphotyrosine and total proteome that were 








CHAPTER 2.  
MATERIALS AND METHODS 
  
 13 
2.1 Plasmids, cloning, antibodies, and reagents – Isogenic SW48 cells used in this study 
were purchased from Horizon Discovery. Cells with heterozygous knock-in of oncogenic 
KRAS mutation G12D (cat. no. HD 103-011) and G13D (cat. no. HD 103-002) were used 
along with the KRAS wild-type parental cells (cat. no. HD PAR-006). All cells were 
cultured in RPMI 1640 supplemented with fetal bovine serum (FBS), L-glutamine, and 
antibiotics, which were purchased from Invitrogen (Carlsbad, CA). RPMI 1640 SILAC 
media deficient in L-lysine and L-arginine were from Thermo Fisher Scientific (Waltham, 
MA). SILAC amino acids; 2H4-Lysine (K4); 13C6, 15N2-Lysine (K8); 13C6-Arginine (R6) 
and 13C6, 15N4-Arginine (R10); were from Cambridge Isotope Laboratories (Andover, 
MA). TPCK-treated trypsin was from Worthington Biochemical Corp. (Lakewood, NJ). 
Anti-phosphotyrosine mouse mAb (P-Tyr-1000) beads for immunoaffinity purification of 
phosphopeptides were from Cell Signaling Technology (Danvers, MA). The primary 
antibodies used in this study were as follows: Antibodies against LGALS1 (12936), PZR 
(9893), and phospho-PZR Y263 (8088) were purchased from Cell Signaling Technology 
(Danvers, MA). Antibodies against ALDH3A1, anti-phosphotyrosine (clone 4G10) were 
purchased from Millipore (Belerica, MA). Antibodies against KRAS (clone F235) and 
TNK2 (clone A-11) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Anti-biotin antibody (Bethyl Laboratories, #150-109A), streptavidin-HRP (Abcam, 
#ab7403), protein G beads (EMD Millipore, #16-266), biotin (Sigma Aldrich, #B4501), 
lipofectamine 2000 (Thermo Fisher Scientific, #11668019). The plasmid pcDNA3.1 
BioID-HA containing the mutant BirA-R118G was purchased through Addgene 
(Cambridge, MA, USA) (Plasmid #36047). The BioID-HA cassette from above plasmid 
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was used to generate pBABE BioID-HA plasmid. The full-length (FL) or N-terminal half 
(ΔC) of TNK2 sequence were cloned in-frame on the N-terminus of BioID-HA. 
2.2 Experimental Design and Statistical Rationale – Three-state stable isotopic labeling 
with amino acids in cell culture (SILAC) of SW48 parental cells, G12D mutant cells, and 
G13D mutant cells was performed. Briefly, cells were cultured in RPMI 1640 SILAC 
media deficient in L-lysine and L-arginine (Thermo Fisher Scientific, Waltham, MA). 
Parental cells were labeled as “light” by culturing in media supplemented with light lysine 
(K0) and light arginine (R0). G12D mutant cells were labeled as “medium” by culturing in 
media supplemented with 2H4-Lysine (K4) and 13C6-Arginine (R6). G13D mutant cells 
were labeled as “heavy” by culturing in media supplemented with 13C6, 15N2-Lysine (K8) 
and 13C6, 15N4-Arginine (R10). Three biological replicates were used for performing 
quantitative analysis of total proteome and phosphotyrosine proteome using high resolution 
mass spectrometry. Significantly regulated phosphosites and proteins were identified by 
ANOVA, and a p-value of 0.05 was denoted as the threshold to determine statistically 
significant changes between two groups. 
2.3 Quantitative SILAC proteomics for BioSITe- Two-state stable isotopic labeling with 
amino acids in cell culture (SILAC) was performed for cells used in this study. Briefly, 
cells expressing mutant TNK2 ΔC-BirA* were labeled as “light” by culturing in media 
supplemented with light lysine (K0) and light arginine (R0). Cell expressing TNK2 FL-
BirA* were labeled as “heavy” by culturing in media supplemented with 13C6, 15N2-
Lysine (K8) and 13C6, 15N4-Arginine (R10). Cells expressing TNK2 FL-BirA* and 
TNK2 ΔC-BirA* were cultured overnight with 50 µM biotin. Cells were lysed in 8 M urea 
buffer (20 mM HEPES pH 8.0, 8 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium 
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pyrophosphate, 1 mM β-glycerophosphate, and 5 mM sodium fluoride), sonicated, and 
then cleared by centrifugation at 15,000 x g at 4 °C for 20 min. Protein concentration of 
lysates was determined by BCA Protein Assay. For each biological replicate, equal 
amounts of protein (10 mg) from each labeling condition was mixed and subjected to 
trypsin in-solution digestion and BioSITe analysis as described below. 
2.4 Immunoprecipitation Experiments and Western blot analysis – Cells were 
harvested and lysed in modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 
mm EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, and 1 mM sodium 
orthovanadate in the presence of protease inhibitors and centrifuged. The supernatant was 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with primary 
and horseradish-peroxidase-conjugated secondary antibodies. For validating 
hyperphosphorylation events, supernatant was subjected to immunoprecipitation with anti-
phosphotyrosine antibodies (4G10). After washing, the immunoprecipitates were resolved 
by SDS-PAGE and assayed by Western blotting using antibodies against proteins of 
interest. 
2.5 siRNA knockdown and proliferation assays – siRNA (10 nM) targeting MPZL1 and 
KRAS were used for transfections with RNAiMax (Thermo Fisher Scientific, Waltham, 
MA). Scrambled siRNA sequence was used as a control. Cells were harvested 36 hours 
post transfection for assessing knockdown efficiency or other follow-up experiments.  
2.6 Trypsin Digestion and Peptide Preparation – Following cell culture, peptides were 
prepared using an in-solution tryptic digestion protocol with slight modifications. In brief, 
frozen pellets of SILAC-labeled cells were lysed in 8 M urea buffer (20 mM HEPES pH 
8.0, 8 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM β-
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glycerophosphate, and 5 mM sodium fluoride), sonicated, and then cleared by 
centrifugation at 15,000 x g at 4 °C for 20 min. Protein concentration of lysates was 
determined by BCA Protein Assay. Twenty milligrams of protein lysates from each 
labeling condition was mixed and subjected to trypsin in-solution digestion. Briefly,the 
resultant mixture was reduced with 5 mM dithiothreitol and alkylated with 10 mM 
iodoacetamide. For in-solution tryptic digestion, the resulting protein extracts were diluted 
in 20 mM HEPES pH 8.0 to a final concentration lower than 2 M urea incubated with 1 
mg/mL TPCK-treated trypsin on an orbital shaker at 25 °C overnight. Protein digests were 
acidified with 1% trifluoroacetic acid (TFA) to quench the digestion reaction and then 
subjected to centrifugation at 2000 xg at room temperature for 5 min. The resulting 
supernatants were desalted using SepPak C18 cartridge (Waters Corporation, Milford, 
MA). Eluted peptides were lyophilized to dryness prior to phosphotyrosine peptide 
enrichment. 
2.7 Affinity Enrichment of Phosphotyrosine Peptides – For phosphotyrosine 
enrichment, 60 mg per replicate of lyophilized tryptic peptides were used. Phosphotyrosine 
rabbit monoclonal antibody kit (PTM Scan, P-Tyr-1000; Cell Signaling Technology, 
Danvers, MA) was used for affinity enrichment of phosphotyrosine peptides. 
Immunoaffinity purification (IAP) of phosphopeptides was carried out as previously 
described (50). Briefly, after lyophilization, 60 mg of peptide mixture was dissolved in 1.4 
ml of IAP buffer (50 mM MOPS pH 7.2, 10 mM sodium phosphate, 50 mM NaCl) and 
subjected to centrifugation at 2000 x g at room temperature for 5 min. Before IAP, P-Tyr-
1000 beads were washed with IAP buffer twice at 4 °C and the pH of the supernatant 
containing peptides was adjusted to 7.2 by adding 1 M Tris Base. For IAP, the supernatant 
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was incubated with P-Tyr-1000 beads at 4 °C for 30 min and the beads were washed three 
times with IAP buffer and then twice with water. Peptides were eluted twice from beads 
by incubating the beads with 0.1% TFA at room temperature. 
2.8 Basic pH Reversed-phase liquid chromatography – The peptide digest was 
fractionated using basic pH RPLC for total proteome analysis. Fractionation was carried 
out at pH 9.5 on a XBridge C18 column (250 × 4.6 mm, 5 µm, 200 A°, Waters Corporation, 
Milford, MA). Peptides were reconstituted in basic pH reversed-phase liquid 
chromatography (bRPLC) solvent A (5 mM triethylammonium bicarbonate (TEAB), pH 
9.5) and loaded on a C18 column using an Agilent 1260 HPLC system. Peptides were 
fractionated by a 70 min gradient of 8–50% solvent B (5 mM TEAB, 90% acetonitrile, pH 
9.5) at a flow rate of 1 mL/min. The peptide fractions were collected in a 96-well plate. 
Fractionated peptides were concatenated into 24 fractions, vacuum dried, and stored at 
−80°C until LC-MS/MS analysis. 
2.9 LC-MS/MS analysis– The peptide fractions were loaded on a 2 cm trap column 
(Acclaim PepMap 100, C18, 5µm particle size, 100 µm i.d. 100 Å pore size, Thermo 
Scientific, San Jose, CA) using 0.1% formic acid with a flow rate 10 µl/min for 5 minutes. 
The peptides were separated on a 50 cm analytical column (Acclaim PepMap 100, C18, 3 
µm particle size, 75 µm i.d. 100 Å pore size, Thermo Scientific, San Jose, CA) with a 100 
min gradient from 7% to 40% acetonitrile in 0.1% formic acid with a flow rate of 300 
nl/min. The spray voltage was set to 2.3 kV while capillary temperature was set to 200°C. 
The samples were analyzed on an Orbitrap Fusion Lumos mass spectrometer (Thermo 
Scientific, Bremen, Germany). The MS instrument was operated in data-dependent 
acquisition mode. A survey full scan MS (from m/z 350–1,550) was acquired in the 
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Orbitrap with a resolution  of 120,000 at m/z 200 with a maximum AGC target value of 
200,000 ions. The data-dependent MS/MS was carried out using the Top Speed method 
with a duty cycle of 3 seconds. Singly charged precursor ions were excluded while 
precursor ions with charge states ≥2 were sequentially isolated to a target value of 50,000 
ions and fragmented in the higher-energy collisional dissociation cell using 32% 
normalized collision energy. The maximum ion injection time for MS and MS/MS were 
set to 60 ms and 100 ms, respectively. Fragment ion spectra were detected in an Orbitrap 
mass analyzer with a resolution 30,000 at m/z 200. Dynamic exclusion was enabled with 
one event of fragmentation followed by the exclusion of the precursor for the next 30 
seconds within 10 ppm of the selected m/z. For all measurements with the Orbitrap 
detector, a lock-mass ion from ambient air (m/z 445.120025) was used for internal 
calibration (80). 
2.10 Mass Spectrometry Data Analysis for pTyr and Global Proteome – Proteome 
Discoverer software suite (v 2.2; Thermo Fisher Scientific, San Jose, CA) was used for 
quantitation and database searches. The MS/MS data were searched using the SEQUEST 
search algorithm against a Human RefSeq database (v73 containing 73,198 entries) 
supplemented with frequently observed contaminants. Additionally, sequence entries 
corresponding to mutant KRAS containing G12D or G13D were added to this database. 
Search parameters used for SEQUEST search algorithm included trypsin as protease with 
full specific and a maximum of one allowed missed cleavage; carbamidomethylation of 
cysteine as a fixed modification; oxidation at methionine as a variable modification. For 
all the 3-State SILAC labeled samples, 13C6, 15N2-lysine, 2H4-lysine, 13C6-arginine and 13C6, 
15N4-arginine were considered as variable modifications. For data analysis of 
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phosphotyrosine enrichments, phosphorylation at tyrosine was additionally selected as a 
variable modification. The precursor tolerance was set at 10 ppm while the fragment match 
tolerance was set to 0.05 Da. The PSMs, peptides and proteins were filtered at a 1% false 
discovery rate cut-off calculated using decoy database searches. For quality control, the 
probability that an identified phosphorylation was modifying each specific Ser/Thr/Tyr 
residue on each identified phosphopeptide was determined from the PhosphoRS algorithm 
(81). Post-processing for phosphotyrosine data was done as follows: After database 
searching, SILAC ratios of peptides were quantified with PyQuant (81). Resulting SILAC 
ratios were maintained at the peptide level and grouped by site, and median values were 
calculated. Additional median normalization was applied to the G12D/Parental ratios and 
G13D/Parental ratios. Finally, the median values from the three replicates were calculated. 
A 2-fold cutoff was selected for hyper-phosphorylation, and a 0.5-fold cutoff was selected 
to denote hypo-phosphorylation. 
2.11 BioSITe- Samples were processed using BioSITe method as previously described by 
Kim et al. (18). Briefly, peptide samples dissolved in BioSITe capture buffer (50 mM Tris, 
150 mM NaCl, 0.5% Triton X-100) were incubated with anti-biotin antibody bound to 
protein-G beads for 2 hours at 4°C. Following incubation, beads were washed multiple 
times with PBS and then washed two times with BioSITe capture buffer, two times with 
50 mM Tris and two times with ultrapure water. Biotinylated peptides were eluted four 
times using elution buffer (80% acetonitrile and 0.2% trifluoroacetic acid in water). The 
eluted sample was further cleaned up using C18 reversed-phase column and subject to LC-
MS/MS analysis. 
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2.12 LC-MS/MS analysis for BioSITe – Peptide samples were analyzed on an Orbitrap 
Fusion Lumos Tribrid Mass spectrometer coupled with the Easy-nLC 1200 nano-flow 
liquid chromatography system (Thermo Fisher Scientific). Peptides were reconstituted 
using 20 μL 0.1% formic acid and loaded on an Acclaim PepMap 100 Nano-Trap Column 
(100 μm x 2 cm, Thermo Fisher Scientific) packed with C18 particles (5 μm) at a flow rate 
of 4 μl per minute. Peptides were separated using a linear gradient of 7% to 30% solvent B 
(0.1% formic acid in 95% acetonitrile) at a flow rate of 300-nl/min over 95 min on an 
EASY-Spray column (50 cm x 75 µm ID, Thermo Fisher Scientific) packed with 2 µm 
C18 particles, which was fitted with an EASY-Spray ion source that was operated at a 
voltage of 2.3 kV. Mass spectrometry analysis was performed in a data-dependent manner 
with a full scan in the mass-to-charge ratio (m/z) range of 300-18,000 in the “Top Speed” 
setting, three seconds per cycle. MS scans for precursor ion detection were measured at a 
resolution of 120,000 at an m/z of 200. MS/MS scans for peptide fragmentation ion 
detection were acquired by fragmenting precursor ions using the higher-energy collisional 
dissociation (HCD) method and detected at a mass resolution of 30,000, at an m/z of 200. 
Automatic gain control for MS was set to one million ions and for MS/MS was set to 0.05 
million ions. A maximum ion injection time was set to 50 ms for MS and 100 ms for 
MS/MS. MS was acquired in profile mode and MS/MS was acquired in centroid mode. 
Higher-energy collisional dissociation was set to 32 for MS/MS. Dynamic exclusion was 
set to 35 seconds, and singly-charged ions were rejected. Internal calibration was carried 
out using the lock mass option (m/z 445.1200025) from ambient air.   
2.13 Post processing and bioinformatics for BioSITe- Proteome Discoverer (v 2.2; 
Thermo Scientific) suite was used for identification. Raw files derived from 3 replicate 
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LC-MS/MS runs, and were searched together. Spectrum selector was used to import 
spectrum from raw files. During MS/MS preprocessing, the top 10 peaks in each window 
of 100 m/z were selected for database searches. The tandem mass spectrometry data were 
then searched using SEQUEST algorithm against protein databases (For BioID 
experiments; Human RefSeq database (v73 containing 73,198 entries) with the addition of 
fasta file entries for TNK2 FL-BirA* and TNK2 ΔC-BirA*. The search parameters for the 
identification of biotinylated peptides were as follows: a) trypsin as a proteolytic enzyme 
(with up to three missed cleavages); b) minimum peptide length was set to 6 amino acids. 
c) peptide mass error tolerance of 10 ppm; d) fragment mass error tolerance of 0.02 Da; 
and e) carbamidomethylation of cysteine (+57.02146 Da) as a fixed modification and f) 
oxidation of methionine (+15.99492 Da), 13C6, 15N2-lysine (K8),13C6, 15N4-arginine 
(R10), biotinylation of lysine (+226.077598 Da), and biotinylation of heavy lysine 
(+234.091797) as variable modifications. Peptides and proteins were filtered at a 1% false-
discovery rate (FDR) at the PSM level using Percolator node (82) and at the protein level 
using protein FDR validator node, respectively. 
 Identified protein and peptide spectral match (PSM) level data were exported as 
tabular files from Proteome Discoverer 2.2. We used PyQuant (19) for obtaining the 
relative quantification of biotinylated peptides with SILAC light or heavy amino acids. To 
derive the precursor ion abundance values for the isotopic counterparts for each 
biotinylated peptide identified from our database search, peak area calculated by PyQuant 
was used. Briefly, PyQuant scans for the light and heavy peptide (K8R10) peaks in the full 
MS1 scan and calculates the peak area over the extracted ion chromatogram (XIC). 
Precursor ion abundances thus computed were used for relative abundance estimates of 
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biotinylated peptides. Missing abundance values in any LC-MS/MS experiment were 
replaced with the minimum value. We used an in-house Python script to compile the 
peptide level site information mapped to UniProt or RefSeq sequences. The summary count 
on the number of biotinylated sites, supported peptides and PSMs and the relative fold-
change information were then calculated at the peptide and protein levels. 
2.14 Data Availability – All mass spectrometry datasets acquired for the study described 
in Chapter 3 was deposited to ProteomeXchange 
(http://proteomecentral.proteomexchange.org) and is available via the PRIDE database 
with the accession number PXD009843. Similarly, the data corresponding to the study 
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3.1 KRAS G12D or G13D mutant cells exhibit distinct features 
Phosphotyrosine signaling has a well-established role in sustaining oncogenic signaling, as 
reflected by the number of targeted therapies directed against molecules in tyrosine kinase 
signaling pathways (83). However, no controlled studies have yet defined the 
phosphotyrosine landscape associated with individual KRAS mutations. As a part of an 
effort to systematically explore the signaling differences between two frequently occurring 
KRAS mutations, G12D and G13D (Figure 3.1A), we examined their tyrosine 
phosphorylation in an isogenic system using parental SW48 human colorectal cells (KRAS 
wild-type) and variants of these cells engineered to harbor two common KRAS mutations 
– G12D or G13D (6). 
The isogenic pair of KRAS mutant cells harboring either G12D or G13D mutations exhibit 
distinct cell morphology (Figure 3.1B). While G12D mutant cells form cell clusters with 
a cobblestone-like morphology, G13D mutants exhibit a fibroblastic morphology with cell 
projections. A previous study has reported that SW48 cells with the G12D mutation show 
increased resistance to EGFR inhibitors than cells expressing the G13D mutation (58).  To 
determine whether our isogenic system also modeled this variation in sensitivity to EGFR 
inhibition, we performed cell proliferation assays. In agreement with previous studies, we 
found that KRAS G12D mutant cells were more resistant to erlotinib than parental or G13D 
mutant cells (Figure 3.1C).  
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Figure 3.1 Distinct phenotypes observed in codon 12 mutations in KRAS. (A) Schematic 
depicting the domain architecture of KRAS protein along with the location of two mutational 
hotspots. Various domains are indicated as colored ovals and the hypervariable region is shown in 
blue at the C-terminus. Amino acid positions of the domains are marked. (B) A photomicrograph 
of parental SW48 colorectal cancer cells or those engineered to contain heterozygous G12D or 
G13D mutations. (C) Effect of treatment with the EGF receptor inhibitor, erlotinib. The parental 
and mutant (G12D or G13D) cells are shown with different colors as indicated.  
  
 26 
3.2 Tyrosine phosphorylation and total proteome landscape in isogenic G12D and 
G13D cells 
To determine whether G12D and G13D KRAS mutations induce different tyrosine 
phosphorylation changes, we performed an initial survey of the global phosphotyrosine 
profile of each mutant using Western blot analysis with an anti-phosphotyrosine antibody. 
We observed that the phosphotyrosine profiles of the two mutants showed distinct 
phosphotyrosine bands with some shared features (Figure 3.2A). In addition, relative to 
parental cells, those carrying a G12D mutation exhibited substantially higher tyrosine 
phosphorylation levels than those harboring the G13D mutation. To identify proteins that 
show altered abundance and phosphorylation, we employed a quantitative proteomics 
approach using stable isotope labeling with amino acids in cell culture (SILAC) (84) by 
growing our cell lines in media supplemented with light or stable heavy isotope labeled L-
lysine and L-arginine amino acids. After culturing cells in respective media, WT (K0, R0), 
G12D (K4, R6), and G13D (K8, R10) cells were combined, lysed and digested with trypsin. 
For total proteome analysis, peptides were pre-fractionated into 24 fractions. For 
phosphotyrosine analysis, phosphotyrosine peptides were enriched using anti-
phosphotyrosine antibodies. These experiments were carried out using biological 
triplicates. LC-MS/MS analysis was carried out on an Orbitrap Fusion Lumos Tribrid mass 
spectrometer (Figure 3.2B). Total proteins and phosphopeptides were identified using a 
1% false discovery rate cutoff. Phosphosites were considered localized if a tyrosine residue 
was assigned with ≥75% probability as calculated by the PhosphoRS algorithm (81). Our 
analysis of the total proteome resulted in the identification of 8,463 proteins. These proteins 
included 166 kinases, 82 phosphatases and 318 transcription factors. Total proteome 
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analysis confirmed the expression of the expected KRAS mutations as we detected MS/MS 
spectra for the isotopically-labeled mutant peptides derived from G12D (Figure 3.2C) or 
G13D KRAS proteins (Figure 3.2D). The detection of peptides corresponding to WT 
KRAS allele in cell expressing G12D and G13D further confirmed the heterozygous nature 
of the mutations in the cells.  
 The phosphotyrosine experiments led to the collective identification of 2,052 
unique phosphotyrosine sites (derived from 667 proteins). Quantitation was performed by 
the program PyQuant (85) which provided quantitation of 875 phosphotyrosine sites 
(derived from 555 proteins), of which 659 sites (derived from 440 proteins) were quantified 
in all three replicates. MS/MS spectra for select phosphotyrosine-modified peptides were 
manually examined to assess the quality of identification. The phosphotyrosine data 
included 80 phosphotyrosine sites derived from 51 kinases, 74 sites in 39 signaling 
adaptor/scaffold proteins and 22 sites in 12 transcription factors. In agreement with the 
Western blot analysis, the distribution pattern for phosphopeptide fold-changes for each 
KRAS mutant relative to WT suggested that the extent of tyrosine phosphorylation was 
indeed higher in G12D cells than G13D or parental cells (Figure 3.2E). Relative to the 
parental cells, G12D-harboring cells exhibited hyperphosphorylation at 53 
phosphotyrosine sites (corresponding to 44 proteins), and G13D cells showed an 
upregulation of 60 (corresponding to 57 proteins). Overall, our data demonstrate that 
despite the previously reported characterization of the global phosphoproteome in the same 
model system (25), our focused analysis of the tyrosine phosphorylated fraction of the 
phosphoproteome revealed many mutant KRAS-induced signaling events that were 
previously uncharacterized. We examined our data for sites that were hyperphosphorylated 
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in one of the mutants but were unchanged or downregulated in the other.  Of the 199 
phosphotyrosine sites within our data that showed a KRAS mutation-specific pattern in 
their hyperphosphorylation, 110 phosphotyrosine sites (corresponding to 88 proteins) show 
increased phosphorylation only in G12D, and 89 sites (corresponding to 83 proteins) 
upregulated only in G13D. 
3.3 Mutant KRAS-induced changes in the tyrosine phosphoproteome 
Our study sought to determine what tyrosine phosphorylation events were 
differentially regulated downstream of KRAS mutations in general. To do this, we 
examined the phosphotyrosine sites showing significant changes (>2 folds and P<0.05) in 
phosphorylation in both KRAS mutants (Figure 3.3A – B). Of the identified differentially 
tyrosine phosphorylated peptides induced by KRAS mutations, 12 phosphotyrosine sites 
(derived from 11 proteins) displayed hyperphosphorylation in both G12D and G13D 
mutant cells (Figure 3.3C). Of the sites with increased tyrosine phosphorylation in both 
KRAS mutants as compared to the parental cells, a subset are derived from kinases, 
including DYRK2 (Y382), FYN (Y185), LYN (Y364), and TNK2 (Y827). Non-receptor 
tyrosine kinase 2 (TNK2) is a cytosolic effector of activated transmembrane RTKs and is 
involved in promoting cancer progression (86–88), were hyperphosphorylated in both 
KRAS mutants. Phosphorylation of Y827, which is located in the EGFR binding domain 
of TNK2, is known to be mediated by Src kinases (89). Representative spectrum data for 
this phosphosite is shown in Figure 3.3D. Furthermore, immunoprecipitation using 
phosphotyrosine specific antibodies and subsequent Western blot analysis for TNK2 
confirmed that overall tyrosine phosphorylation of TNK2 was increased in both KRAS 
mutants (Figure 3.3E). In addition to kinases, phosphosites in several calcium-binding   
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Figure 3.2 Global and phosphotyrosine profiling of KRAS mutant cells. (A) Global 
phosphotyrosine profile of parental and mutant (G12D or G13D) cells revealed by Western blot 
analysis. (B) Schematic of the experimental strategy used for quantitative profiling of 
phosphotyrosine and total proteomes. (C-D) Representative MS/MS spectra showing identification 
of peptides corresponding to G12D mutant (C) and G13D mutant (D) as indicated. Fragment ions 
confirming the presence of amino acid substitutions are indicated in red. (E) Distribution of log2-
transformed ratios for tyrosine phosphopeptides (G12D/Parental and G13D/Parental). 
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proteins, including ANXA2 (Y48, Y256), CALM2 (Y100), and ITSN2 (Y968), were 
hyperphosphorylated in both KRAS mutants. Calmodulin (CALM2) has a well-established 
role in mutant KRAS signaling and is also a known RAS binding partner (13,90,91). 
Further studies need to be conducted to investigate the particular signaling events leading 
to these tyrosine hyperphosphorylation events downstream of mutant KRAS. We 
hypothesize that these changes downstream of mutant KRAS proteins may, in part, be a 
result of differential binding of canonical wild-type KRAS effectors, or binding and 
recruitment of novel downstream effectors. 
3.4 Mutant KRAS-induced changes in the total proteome 
  In addition to phosphotyrosine signaling, we also sought to comprehensively map 
the changes in protein expression in the presence of mutant KRAS. Our quantitative 
analysis revealed that relative to parental cells, 134 and 182 proteins were significantly 
more abundant (2-fold or higher; p ≤0.05) in G12D (Figure 3.4A) and G13D (Figure 3.4B) 
cells, respectively. Of these, 44 proteins were upregulated downstream of both KRAS 
mutations (Figure 3.4C). This set of proteins included several cell surface molecules such 
as surface proteoglycan/glycoproteins (CD99 and GPC1), tetraspanins (CD63 and CD151) 
and TNF receptor superfamily member 12A (TNFRSF12A). This included upregulation of 
CD73, a GPI-anchored enzyme, which catalyzes the conversion of AMP to adenosine and 
is being pursued as a target for cancer immunotherapy. Upregulation of CD73 in 
cells/tumors expressing mutant KRAS has been previously reported by multiple studies 
including proteomic studies that reported CD73 upregulation in MCF10A cells expressing 
the KRAS G12V mutant (92). Overexpression of this protein in human colorectal cancer 
tumors is correlated with a poorer survival (93,94). Other upregulated molecules included 
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Figure 3.3. Mutant KRAS-induced changes in the tyrosine phosphoproteome. (A-B) Volcano 
plots depicting relative differences in phosphotyrosine sites between parental cells and (A) G12D 
mutated and (B) G13D mutated cells. The ratio of relative intensity of phosphotyrosine peptides in 
individual KRAS mutants versus parental cells is shown on the x-axis (log2-transformed). The y-
axis shows the p-values (log2-transformed). The vertical red/blue lines indicate 2-fold changes in 
the abundance ratios and the horizontal green line signifies a p-value cutoff of 0.05. Phosphosites 
showing statistically significant (p-value ≤ 0.05) hyper- or hypo-phosphorylation are marked in red 
or blue, respectively. Selected phosphoproteins/sites are labeled. (C) Venn diagram showing the 
set of tyrosine phosphorylation sites hyperphosphorylated in both or individual KRAS mutant cells 
(D) Representative MS/MS spectrum of phosphopeptide corresponding to TNK2 pY827. Fragment 
ions confirming the localization of the phosphotyrosine site are indicated in red. Representative 
MS1 level spectrum used for quantifying relative abundance in parental, G12D mutant (red), and 
G13D mutant (blue) cells is shown as an inset.  (E) Western blot analysis of anti-phosphotyrosine 
immunoprecipitates from parental and mutant cells using protein-specific antibodies against non-
receptor tyrosine kinase 2 (TNK2). 
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proteins associated with DNA replication, recombination, and repair, specifically members 
of the mini chromosome maintenance complex (MCM complex) which has a role in DNA 
unwinding (MCM2, MCM3, MCM4, MCM5 and MCM6). Both KRAS mutants showed 
upregulation of DNA damage response activators, including Fanconi anemia 
complementation group G (FANCG), MHC class I polypeptide-related sequence A 
(MICA), and macrophage migration inhibitory factor (MIF). Consistent with the known 
role of mutant KRAS in driving metabolic reprogramming of cancer cells (95,96), we also 
observed upregulation of enzymes involved in fatty acid metabolism (UBE2L6, GPD2 and 
ACSL5). Finally, several upregulated proteins identified in our analysis have not been 
previously reported or characterized in the context of mutant RAS-induced signaling, such 
as transmembrane protein 2 (TMEM2), GTP cyclohydrolase I feedback regulatory protein 
(GCHFR), Kallikrein Related Peptidase 10 (KLK10), FAM122B, KIAA1524, and 
gasdermin D (GSDMD). We used Western blot analysis to validate some of the common 
protein alterations observed in our MS data including CD73 (5'-nucleotidase ecto), HSPB1 
(heat shock protein beta-1) and KRAP (KRAS-induced actin-interacting protein) (Figure 
3.4D). Overall, our global proteome analysis of isogenic KRAS mutant cells represents a 
resource for understanding the protein expression changes that are induced upon 
endogenous expression of two of the most common KRAS mutations in cancer. 
3.5 Unique tyrosine hyperphosphorylation events downstream of KRAS G12D and 
G13D 
 We observed 110 phosphotyrosine sites in 88 proteins to be hyperphosphorylated 
in G12D, that were unchanged or decreased in G13D (Figure 3.5A). This signature 
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Figure 3.4 – Mutant KRAS-induced signatures in the total proteome. (A-B) Volcano plots 
depicting relative differences in total protein abundances between parental cells and (A) G12D 
mutated and (B) G13D mutated cells. The ratio of relative intensity of a protein in individual KRAS 
mutants versus parental cells is shown on the x-axis (log2-transformed). The y-axis shows the p-
values (log2-transformed). The vertical red/blue lines indicate 2-fold changes in the abundance 
ratios and the horizontal green line signifies a p-value cutoff of 0.05. Proteins showing statistically 
significant (p-value ≤ 0.05) up-regulation or down-regulation are marked in red or blue, 
respectively. Selected proteins are labeled. (C) Venn diagram showing the set of proteins showing 
increased abundance in both or individual KRAS mutant cells relative to parental cells. (D) Western 
blot analysis of whole cell lysates from parental and mutant cells using a protein-specific antibodies 
directed against 5'-nucleotidase ecto (CD73), KRAS-induced actin-interacting protein (KRAP), 
and heat shock protein beta-1 (HSPB1). 
  
 34 
included hyperphosphorylation of sites in kinases, including MET (Y1003), MAPK3 
(Y204), and MINK (Y735). Several G12D-induced phosphorylation changes involved 
proteins and/or phosphosites that are not well-studied. For instance, hyperphosphorylation 
of Y546 in FAM171A2 (family with sequence similarity 171, member A2), a poorly 
characterized integral membrane protein, was observed only in G12D mutant cells. We 
also observed hyperphosphorylation of discoidin, CUB, and LCCL domain containing 2 
(DCBLD2) at Y715, a site that was reported to undergo phosphorylation mediated by 
upstream Src tyrosine kinases, resulting in a binding site for the SH2 domain of CRKL 
(97). One of the G12D-specific features was the hyperphosphorylation of myelin protein 
zero-like 1 (MPZL1) protein (Y263). The MPZL1 protein is a single-pass transmembrane 
glycoprotein involved in extracellular matrix-induced signaling and regulation of cell 
adhesion. Increased phosphorylation was observed at Y263, a site localized within the 
cytoplasmic Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) that is known to 
recruit and activate protein tyrosine phosphatase, non-receptor type 11 (PTPN11) (98–
101). Phosphorylation of this site is regulated by c-Src and controls the activation status of 
MPZL1 (102). To validate the G12D-specific hyperphosphorylation of this site as indicated 
by our quantitative MS data, Western analysis using an antibody specific for 
phosphorylated Y263 was performed. As shown in (Figure 3.5C), our analysis revealed 
hyperphosphorylation of MPZL1 at Y263 specifically in G12D cells but not in G13D cells. 
In addition, multiple proteins involved in focal adhesion and adherens junctions exhibited 
G12D-specific hyperphosphorylation at one or more sites. These included CTNNB1 
(Y654), PKP3 (Y99), PKP4 (Y114, Y224, Y261, Y425, Y950), PLEKHA7 (Y1035), and 
TNS3 (Y896). Finally, our data also highlighted other notable proteins showing 
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hyperphosphorylation in this mutant including enhancer of rudimentary homolog (ERH-
Y92) a protein shown to be synthetically lethal in mutant KRAS cells (45). Collectively, 
our findings from the analyses of the tyrosine phosphoproteome bring to attention several 
G12D mutation-specific phosphorylation events that warrant further investigation for their 
potential involvement in G12D-specific oncogenic phenotype. 
 To understand the tyrosine phosphorylation changes occurring uniquely 
downstream of the G13D mutation, we examined the 32 phosphotyrosine sites 
(corresponding to 32 proteins) that were hyperphosphorylated only in G13D cells. Among 
these sites were those mapping to MAPK family kinases, which included MAPK7 (Y227), 
MAPK9 (Y185), and MAPK10 (Y223). Pathway analysis revealed G13D-specific 
hyperphosphorylation of many proteins involved in catalyzing diverse metabolic cellular 
processes. This group included phosphosites in ACLY (Y736), ATIC (Y293), CALU 
(Y114), CPOX (Y332), ISOC1 (Y106), TXNRD1 (Y163), and UBE2E3 (Y91). Other 
tyrosine hyperphosphorylation events induced by the G13D mutation involved proteins in 
regulating GTP/GDP binding (ARHGAP42 (Y376), GDI2 (Y203), RAB10 (Y6), WASL 
(Y256)), RNA translation (GARS (Y453), ICT1 (Y49)), and protein processing and folding 
(HSP90B1 (Y94), PPIB (Y47), PSMA2 (Y76)). Overall, our analysis reveals that the 
phosphotyrosine changes induced by the G13D mutation differed significantly from those 
induced downstream of G12D mutation, and mostly impacts proteins involved in the 
regulation of enzymatic activity and assorted metabolic process. 
3.6 Unique protein expression changes downstream of KRAS G12D and G13D 
 To identify proteins that exhibited significant changes in abundance downstream of 
each KRAS mutation, we focused on proteins that showed a ≥2-fold change (P<0.05) 
between the mutants ((G12D/Parental)/(G13D/Parental)) (Figure 3.5B). Within this set of 
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proteins (n = 356), we found 47 proteins that showed statistically significant (p <0.05) 
upregulation only in G12D, which included several cell surface proteins such as CD44, 
CD59, EPCAM, ITGA2, ITGA3, ITGB1, LGALS1 and MET. Western blot analysis 
confirmed the upregulation of Hepatocyte growth factor receptor (MET), galectin-1 
(LGALS1), and Heparan sulfate proteoglycan (CD44) (Figure 3.5D). In addition to MET 
receptor tyrosine kinase, we found several other kinases that showed G12D-specific 
upregulation, including calcium/calmodulin dependent protein kinase II delta (CAMK2D), 
protein kinase N1 (PKN1), Rho associated coiled-coil containing protein kinase 2 
(ROCK2), serine/threonine kinase 4 (STK4) and TANK binding kinase 1 (TBK1). 
Interestingly, TBK1 is a known synthetic lethal partner of oncogenic KRAS, which has 
been demonstrated to be essential for survival of cells harboring mutant KRAS (103).We 
also observed G12D-specific upregulation of proteins that are part of multi-protein 
complexes, such as subunits of heterotrimeric G-protein complex (GNAI1, GNAI2, 
GNAI3, GNAS), components of the NDC80 kinetochore complex (NDC80, SPC24, 
SPC25), trafficking protein particle complex (TRAPPC2L, TRAPPC4, TRAPPC5), TTT 
complex (TTI1, TTI2) and cavins (CAVIN1, CAVIN3). However, the large majority of 
the proteins showing G12D-specific upregulation were involved in metabolic processes 
and pathways, including those that drive glycolysis (ENO2, PFKP, GPC4, G6PD, GNE,  
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Figure 3.5 KRAS point mutation-specific rewiring of phosphotyrosine proteome in isogenic 
cells. (A) Volcano plot depicting relative differences in phosphotyrosine peptides in the two KRAS 
mutant cells. The ratio of relative intensity of phosphotyrosine peptides in G12D versus parental to 
the relative intensity of phosphotyrosine peptides in G13D versus parental is shown on the x-axis 
(log2-transformed). The y-axis shows the p-values (log2-transformed). The vertical red line 
indicates 2-fold changes in the ratios and the horizontal green line signifies a p-value cutoff of 0.05. 
Phosphosites showing statistically significant (p-value ≤ 0.05) hyper- or hypo-phosphorylation are 
marked in red or blue, respectively (B) Volcano plot depicting relative differences in total protein 
abundances in the two KRAS mutant cells. The ratio of relative intensity of a protein in G12D 
versus parental to the relative intensity of a protein in G13D versus parental is shown on the x-axis 
(log2-transformed). (C) Western blot analysis of whole cell lysates from parental and mutant cells 
using a phosphosite-specific antibody directed against Y263 of MPZL1. (D) Western blot analysis 
of whole cell lysates from parental and mutant cells using a protein-specific antibody directed 
against Hepatocyte growth factor receptor (MET), galectin-1 (LGALS1), and Heparan sulfate 
proteoglycan (CD44). (E) Western blot analysis of whole cell lysates from parental and mutant 
cells using a protein-specific antibody directed against Aldehyde Dehydrogenase 3 Family Member 
A1 (ALDH3A1), LIM domain only protein 7 (LMO7), and FKBP family of peptidyl-prolyl 
cis/trans isomerases (FKBP11). 
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ME2) or are involved in fatty acid/lipid metabolism (ABCD3, ABHD10, ACAD9, ACSL3, 
CRAT, ECHDC1, ENO2, IDH2, ME2, MECR, PGD, PTGR1 and ZADH2). Further, 
upregulation of proteins associated with the inner mitochondrial membrane (BPHL, CNP, 
COX20, MRPS16, PISD, TIMM23, TOMM34 and UQCRQ), and other proteins with 
general oxidoreductase activity (ACADSB, ALDH4A1, ALDH6A1, BLVRA, FOXRED2, 
G6PD, MICAL1, NDUFA13, NDUFA8, NDUFB9, PTGR1, SCD and VKORC1) were 
unique to cells harboring the G12D mutation. Finally, G12D-specific upregulation of 
several transcription factors (CSRP2, HDAC1, MBD2, PMF1, TAF5, TRIM26, TSC22D1) 
was also observed. Analysis of proteins showing a KRAS G13D mutation-specific increase 
in protein abundance (n = 68) included cell surface markers (CD109, FAS, SDC1), 
cytokines (FAM3C, IL18), several kinases (CAMK1, MAP3K6, ROCK1, RPS6KA3) and 
transcription factors (FHL2, LMO7, PML, SMAD3, STAT1, ZNF185).  Components of 
the laminin complex (LAMA3, LAMB3, LAMC2) were also among the proteins 
preferentially upregulated in G13D mutated cells. Western blot analysis confirmed the 
upregulation of aldehyde dehydrogenase 3 family member A1 (ALDH3A1), galectin-3 
(LGALS3), and FK506 binding protein 11 (FKBP11) in G13D cells (Figure 3.5E). G13D-
specific upregulation of ALDH3A1 was also observed previously and served as a positive 
control (77). Overall, our analysis provides an in-depth characterization of differences in 
the protein expression changes induced by each KRAS mutation, and highlights molecules 
and pathways that may be of specific importance in sustaining oncogenic signaling in a 
mutation-specific manner.  
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3.7 MPZL1, an ill-characterized cell surface glycoprotein, is a novel molecule 
downstream of mutant KRAS 
 Some of the tyrosine phosphorylation events that are uniquely induced by either 
KRAS mutation may be crucial for maintaining their oncogenic signaling. It is also 
possible that proteins showing increased tyrosine phosphorylation downstream of the 
G12D mutation may be involved in conferring resistance to EGFR inhibitors. To test this, 
we performed siRNA knockdown of MPZL1, a relatively understudied cell surface 
glycoprotein that showed G12D-specific tyrosine hyperphosphorylation in our analysis 
(Figure 3.5C). Analysis of publicly available datasets for genes that show synthetic 
lethality (37,40) with mutant KRAS revealed that compared to wild-type cells, KRAS 
mutated cells are significantly more dependent on expression of MPZL1 (Figure 3.6A). 
To assess the importance of MPZL1 in parental or mutant cells, we performed a cell 
viability assay using cells transfected with either control/scramble siRNA or siRNA 
targeting MPZL1. Knockdown of MPZL1 led to decreased viability of G12D mutant cells 
specifically, suggesting a selective importance of this protein in sustaining G12D mutant 
cells (Figure 3.6B). As a positive control, we assessed changes in viability of parental and 
mutant cells transfected with control or KRAS targeting siRNA. As expected with 
oncogene addiction/dependency (104), knockdown of KRAS resulted in decreased 
viability of G12D and G13D mutant cells, but not parental cells (Figure 3.6C). Finally, we 
assessed the impact of MPZL1 knockdown on each cell line’s response to the EGFR 
inhibitor erlotinib by treating cells transfected with either control or MPZL1 siRNA with 
varying concentrations of erlotinib. Relative to control siRNA transfected cells, we 
observed a  
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Figure 3.6. Knockdown of MPZL1 leads to decreased cell viability and increased 
sensitivity in G12D mutant cells. (A) Cells harboring KRAS mutations are significantly 
more sensitive to MPZL1 knockdown compared to wild-type cells. Data and plot were
obtained from genetic dependency datasets available through the CancerGD resource 
(www.cancergd.org) (40). (B) Cell proliferation assays using parental and mutant cells 
transfected with either control siRNA (si-scrambled) or siRNA against MPZL1 (si-
MPZL1). Percentage cell viability was calculated relative to cells treated with control 
siRNA. Results for each group were derived from four replicates. P-value was calculated 
using a paired t-test. (C) Cell proliferation assays using parental and mutant cells 
transfected with either control siRNA (si-scrambled) or siRNA against KRAS (si-KRAS). 
(D) Cell proliferation assays using erlotinib-treated parental and mutant cells that were 
transfected with either control siRNA (si-scrambled), siRNA against MPZL1 or KRAS.   
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targeted decrease in viability of erlotinib-treated G12D mutant cells that were transfected 
with siRNA against MPZL1 suggesting an increase in sensitivity of G12D mutant cells to 
EGFR inhibition (Figure 3.6D). Collectively, these preliminary studies suggest a targeted 
functional importance of MPZL1 in signaling downstream of the KRAS G12D mutation 
(Figure 3.7). Although further studies are needed to describe and assess the role of MPZL1 
in normal and mutant RAS signaling, our analysis underscores this molecule as a potential 
therapeutic candidate in KRAS, specifically G12D, mutated cancers. 
3.8 Conclusions 
 Although KRAS, one of the earliest discovered proto-oncogenes, has been the focus 
of a large number of studies over the last few decades, several aspects of its biology 
including the subtle biological differences present between the point mutations, still remain 
a mystery. In this study, we chose an approach that not only permitted us to specifically 
determine the signaling differences between two common mutations, G12D and G13D, but 
also allowed a deeper understanding of signaling events impacted by mutant KRAS in 
general. Enrichment of phosphotyrosine-containing peptides allowed us to probe 
phosphotyrosine signaling pathways, which have become important therapeutic targets in 
cancer. Incorporation of a SILAC strategy allowed us to more precisely characterize the 
subtle differences in tyrosine phosphorylation-mediated signaling downstream of the two 
KRAS mutations. Finally, the power of this unbiased approach was demonstrated in our 
study through the identification of numerous unsuspected and novel molecules that, owing 
to their low abundance or limitations of previous approaches, have not been linked with 
oncogenic RAS signaling. With the advent of CRISPR/Cas9 technology, the ability to 
quickly develop isogenic model systems engineered to harbor various mutations/fusions of 
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interest has become widely accessible. We believe that the coupling of our approach to 
genomic engineering through CRISPR/Cas9 technology is an excellent strategy for 
investigating signaling by related oncogenes.  
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Figure 3.7 Schematic model depicting MPZL1 as a signaling node in KRAS G12D 
mutation-specific signaling. Select protein domains of MPZL1, such as extracellular Ig-
like domain (purple), transmembrane domain (grey) and immunoreceptor tyrosine-based 






PROXIMITY-DEPENDENT BIOTINYLATION TO 
ELUCIDATE THE INTERACTOME OF TNK2 NON-
RECEPTOR TYROSINE KINASE   
 45 
 The dynamic assembly and disassembly of protein complexes is a fundamental 
principal that drives biological processes. Compared to other non-receptor tyrosine kinases, 
reported studies on TNK2 are specifically lacking in focus on characterizing its 
intracellular molecular binding partners and their contribution to the role of TNK2 in 
normal and oncogenic signaling. Herein, we describe how we performed a quantitative 
analysis of protein biotinylation with a site-level resolution as a means to identify TNK2 
proximal proteins in the context of a breast cancer cell line.  
4.1 Application of BioSITe for the discovery of TNK2 interactors 
We took advantage of the BioID system to identify interactors of TNK2. For this, 
we generated a full-length TNK2 construct fused with BirA* at C-terminal of TNK2 
(Figure 4.1A). We also generated a TNK2 C-terminal deletion BirA* fusion construct with 
the deletion of the C terminal moiety of TNk2 (ΔC) that was lacking important regions that 
mediate TNK2 interaction with other proteins, including the Proline-rich domain, the 
EGFR-binding domain (EBD), and the ubiquitin association domain (UBA) in the C-
terminus of TNK2. This construct also served as a control to allow us to more clearly 
differentiate the interacting partners of the functional full-length TNK2 protein. The full 
length TNK2 (FL) and truncated TNK2 (ΔC) constructs were respectively transfected into 
HEK293T cells for packaging viral particles that were used to infect HCC1395 cells and 
stable cell lines were generated by puromycin selection. Relative expression levels of 
BirA*-tagged TNK2 FL, and ΔC were analyzed by immuno-blot with both anti-HA tag 
and anti-TNK2 antibodies, showing the different molecular weights of TNK2 protein 
variants. Western blot analysis using an HA tag and TNK2 specific antibody confirmed the 
expression of both constructs at their expected molecular weights (Figure 4.1B). To 
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confirm an increase in global intracellular biotinylation in cells stably expressing TNK2 
BirA* fusion constructs, we performed western blot analysis using anti-biotin antibody on 
whole cell lysates from stable cells cultured in growth medium with or without exogenous 
biotin overnight. As expected, relative to parental cells and cells not treated with biotin, 
our BirA* cells incubated with biotin showed an increased global biotinylation signature, 
which included visibly increased biotinylation of the TNK2-BirA* fusion proteins 
themselves (Figure 4.1C). To systematically map the molecular interactors specific to the 
canonical full-length TNK2 protein, we opted for a quantitative approach by incorporating 
stable isotope labeling amino acids in cell culture (SILAC) (105). The stable cell lines with 
FL TNK2 or ΔC TNK2 were labeled by growing in heavy (K8, R10) and light (K0, R0) 
amino acids supplemented SILAC media, respectively, and treated overnight with 
exogenous biotin (Figure 4.1D). The cells were harvested, lysed, mixed and then digested 
with trypsin. To identify proteins biotinylated downstream of full-length or truncated 
TNK2 protein, we employed a method recently developed in our lab that allows the site-
specific analysis of biotinylation on peptides via mass spectrometry analysis (106). Using 
whole cell lysates derived from SILAC-labeled breast cancer cells (HCC1395) expressing 
either ΔC mutant (Light) or wild-type (Heavy) TNK2-BirA*, we performed 
immunoaffinity-based enrichment of biotinylated peptides using an anti-biotin antibody. 
4.2 Mass spectrometry and data analysis to identify and quantify biotinylated 
peptides and proteins 
 As part of our strategy of applying proximity-based biotinylation for mapping the 
intracellular protein interactors of TNK2, we acquired quantitative mass spectrometry data 
from the analysis of enriched fractions of biotinylated peptides derived from three   
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Figure 4.1 Overview of SILAC-BioSITE quantitative workflow for mapping TNK2 
interactome in breast cancer cells (A) Schematic depicting the protein domains within 
recombinant TNK2 full length (top) and ΔC mutant (bottom) constructs used in this study. 
A biotin ligase (BirA*) and HA tag were cloned in-frame at the C-terminus of both variants 
as indicated. (B) Western blot analysis of whole cell lysates from breast cancer cells 
(HCC1395) to confirm expression of TNK2 FL-BirA* or ΔC-BirA*constructs. Analysis 
was performed using antibodies against TNK2 and HA-tag. (C) Western blot analysis of 
global biotinylation using whole cell lysates from parental cells and cells expressing TNK2 
FL-BirA* or ΔC-BirA*. Analysis was performed using a biotin-specific antibody. (D) 
Experimental workflow for differential interactome analysis of SILAC-labeled HCC1395 
cells expressing full-length (Heavy) or ΔC mutant (Light) TNK2-BirA* fusion constructs 
were incubated overnight with media containing biotin. Equal amounts of cell lysates from 
each condition were mixed and digested into peptides. Biotinylated peptides were enriched 






biological replicates. LC-MS/MS analysis using an Orbitrap Fusion Lumos generated three 
raw mass spectrometry files that were then subjected to spectral matching via a combined 
database search. Our experimental design called for a search scheme that could identify 
SILAC labeled or unlabeled peptides modified with biotin at one or more/all lysines. To 
consider all such peptides, we configured our database search parameters to consider the 
presence of numerous variable modifications, including SILAC modification of lysine and 
arginine (Lys8, Arg10) biotinylation of light (Lys-Biotin) as well as SILAC-modified 
lysine (Lys8+Biotin) (Figure 4.2A). We also allowed for 3 missed cleavages to account 
for the lack of cleavage by trypsin after lysines with biotinylated sidechains. Database 
spectral matching with the above parameters led to the identification of 688 unique 
biotinylated peptides corresponding to 367 biotinylated proteins. When possible, MS/MS 
spectra were manually examined to check for the presence of signature fragment ions, such 
as those resulting from biotinylated heavy (m/z = 316.17) and light (m/z = 310.15) lysines 
(107), and to confirm the presence and quality of fragments covering the annotated 
biotinylation site. 
The list of biotinylated peptides identified from the coupled use of SILAC-labeling with 
BioSITe called for an adequate quantitation platform. As depicted in Figure 4.2A, the 
biotinylated peptides in our study could be present in multiple forms and could be 
isotopically-labeled (Lys8), biotinylated, or both. With the added consideration of 
miscleaved peptides, these parameters collectively lead to a massively large search space, 
resulting in failure to quantify certain peptides with multiple dynamic modifications, 
making quantification of peptides with multiply modified lysines quite challenging. Using 
a quantification workflow that integrated PyQuant, a quantification algorithm previously  
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Figure 4.2 Computational approach to identify and quantify biotinylated peptides.
The in-silico pipeline used for processing raw files to identify and quantify biotinylated 
peptides is depicted. Raw files were processed to generate a list of biotinylated peptide IDs. 
(A) Workflow used to identify biotinylated peptides sequences and proteins. Relevant 
details regarding parameters used for the automated database search, such as dynamic 
modification and mass tolerance thresholds are indicated. Strategy used when manually 
examining spectra is also depicted. The workflow used to quantify the identified 
biotinylated peptides is also summarized. Quantification was performed by configuring the 
pipeline offered by PyQuant as described previously (1).  
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developed by our group (108), we derived MS1 level quantification for the list of identified 
biotinylated species and their corresponding isotopic counterparts (Figure 4.2A). This 
enabled us to get quantitation for a large majority of the identified biotinylated peptides 
and proteins. As with the results from database identification, we manually examined MS1 
spectra for a selection of biotinylated candidates to confirm the validity of the relative 
abundance as reported by PyQuant. Representative MS2 along with the corresponding 
MS1 spectrum used for deriving relative quantification are shown for biotinylated peptides 
from NCK interactor 1 (NCK1) (Figure 4.3A), Cortactin (CTTN) (Figure 4.3B), Clathrin 
interactor 1 (CLINT1) (Figure 4.3C) and TELO2-interactor 1 (TTI1) protein (Figure 
4.3D). 
4.3 Identification of TNK2 proximal interactome using BioSITe 
Our group has previously shown that in the analysis of data derived from a BioSITe 
study, the degree of protein biotinylation can be used as a potential metric to help prioritize 
confident protein interactors from potential contaminants and false positives (106). 
Therefore, we grouped the biotinylated proteins in our data based on their degree of 
biotinylation (Figure 4.4A). As expected, this resulted in the sorting of TNK2 bait protein 
as the protein showing the highest degree of biotinylation. TNK2 is known to bind to itself 
and form homo-dimers (109). Therefore, in addition to autologous biotinylation, 
identification of biotinylated peptides mapping to TNK2 may in part be a result of TNK2 
self-dimerization. However, we did not observe many of the well-established direct binders 
of TNK2 among the proteins showing the highest degree of biotinylation. In search for true 
interaction partners of TNK2, we next examined the set of biotinylated sites and proteins  
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Figure 4.3 Representative MS/MS and MS spectra used for identification and relative 
quantitation of biotinylated peptides derived from cells expressing TNK2-BirA* 
constructs. (A) MS/MS fragmentation of a biotinylated peptide mapping to NCK adaptor 
protein 1 (NCK1), a known binding partner of TNK2. Representative MS1 spectrum used 
for deriving relative quantification between full-length and ΔC mutant cells is shown as an 
inset. Fragments ion that confirm the annotated site of biotinylation are shown in red. 
Signature fragment ions resulting from biotinylated lysine moieties are indicated in green. 
(B) Representative MS/MS and MS1 spectra of biotinylated peptides mapping to K272 in 
cortactin (CTTN), a known interactor and phosphorylation substrate of TNK2. (C) 
Representative MS2 and MS spectra of biotinylated peptides mapping to selected novel 
TNK2 interactors such as (C) clathrin interactor 1(CLINT1) and (D) TELO2-interacting 
protein 1 (TTI1).  
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that showed a significantly higher abundance in cells expressing full-length TNK2 relative 
to cells expressing a truncated version of the protein. This led to the identification of 57 
biotinylation sites mapping to 40 biotinylated proteins that displayed a ≥2-fold higher 
abundance in cells expressing full-length relative to truncated protein (referred to from here 
on as full length specific TNK2 binders). Among these were biotinylation sites mapping to 
several experimentally established TNK2 binders, including NCK adaptor protein 1 
(NCK1), NCK adaptor protein 2 (NCK2) (110,111), cortactin (CTTN) (112), clathrin 
(CLTC) (113), and Cyclin G associated kinase (GAK). Some of our biotinylated candidates 
overlapped with those identified in previous co-immunoprecipitation experiments using 
recombinant TNK2, including STAT3 (K707) and CRKL (K89). Analysis in the previous 
study also showed that TNK2 was involved in phosphorylation of STAT3 at Y705, and 
that this process is partly regulated by HSP90 (114). In line with these reports, we also 
observed increased biotinylation of several heat shock protein complex components in the 
cells expressing full-length TNK2-BirA*, including HSP8 (K507, K512), HSP90AB1 
(K607), and HSPA1A (K507). Furthermore, while CRKL was identified in the above 
study, we also found biotinylated peptides mapping to CRK, which is not a known TNK2 
binder. Overall, these findings indicate that the relative abundance ratio for biotinylation 
sites/peptides between full-length and truncated constructs can serve as a powerful 
differentiator between true binders of the biotin ligase fused bait protein and background 
or false positives. In this study, this strategy allowed us to identify true binders of TNK2 
protein by relative comparison of protein biotinylation between cells expressing full-length 
TNK2 and truncated TNK2.  
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Figure 4.4. Mapping of TNK2 interactome using biotinylation sites. (A) Biotinylated 
proteins identified by BioSITe are shown grouped by the degree of biotinylation in cells 
expressing TNK2 constructs fused with biotin ligase. The number of biotinylated proteins 
falling within each group are indicated. For each group, 10 representative biotinylated 
proteins are shown. The number of biotinylated lysines out of the total number of lysines 
are provided for each protein. Known binding partners of TNK2 are shown in red. (B) 
Domain schematics for select biotinylated proteins identified in this study. The protein 
domains and the relative localization of the biotinylation sites mapped to the protein are 
shown. The full names of the protein domains are described in the legend. Sites showing a 
2-fold or greater change in abundance ratio between TNK2 FL-BirA* and TNK2 ΔC-
BirA* are labeled in red. 
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In addition to identifying sites of biotinylation on several proteins that overlap with 
published interactors and substrates of TNK2, our BioSITe data also included many 
biotinylated proteins that have not been previously reported to be associated with TNK2 
and could be potentially novel TNK2 interactors. These interaction candidates included 
clathrin interactor 1 (CLINT1), TELO2 interacting protein 1 (TTI1), NADPH oxidase 
activator 1 (NOXA1), RuvB like AAA ATPase 1 (RUVBL1), and GRB10 interacting GYF 
protein 2 (GIGYF2). We noted that several of the novel interaction candidates for TNK2 
are proteins that bind known interactors of TNK2, as determined by previously reported 
studies. For instance, comparison of 101 known CLINT1 interactors with known TNK2 
interactors indicates common binding to several well-characterized TNK2 interactors, 
included CLTC, GAK, NCK1, GTSE1, and NTRK1. Similarly, in the database derived 
interactome for TTI1 (n = 47), an important member of the mTORC protein complexes 
(115), binds EGFR and NTRK1. 
 TNK2 is known to bind SH3 domains through its proline rich domain (116–118). 
To test for an enriched presence of SH3 and potentially other protein domains that mediated 
molecular association with proteins, we performed analyses to determine whether proteins 
showing full-length specific biotinylation were enriched in certain protein domains, and 
also whether the site of biotinylation in these putative TNK2 binding partners were 
preferentially localized to specific protein domains and regions. A more in-depth 
examination of biotinylation site localization in the context of the annotated domains in 
individual proteins revealed that many sites mapped to known protein domains and motifs, 
namely SH3 domains (CRK, CTTN, DNMBP, NCK1, NCK2, NOXA1, STAM2, TNK2, 
UBASH3B) and the ENTH domain which is involved primarily in mediating binding to 
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membrane lipids (CLINT1, HGS, HIP1, STAM2, TTI1). A few selected biotinylated 
proteins and the location of biotinylation sites with their linear protein structure is depicted 
in Figure 4.4B. Furthermore, we observed that while several proteins in our data were 
found biotinylated at multiple sites, the relative abundance of the biotinylated peptides 
mapping to regions adjacent to these protein domains were often more abundant in cells 
expressing full-length TNK2 where the proline-rich domain is conserved. 
4.4 TNK2 proximally-biotinylated proteins are involved in vesicle-mediated 
endocytosis 
A collective survey of previous studies available on TNK2 indicates its association with 
pathways involved in recycling of surface receptors, especially receptor tyrosine kinases 
such as Epidermal growth factor receptor (EGFR), Insulin receptor, and AXL receptor 
tyrosine kinase (119–121). However, the specific proteins and protein complexes engaged 
by TNK2 to drive these processes have not been properly surveyed previously. Thus, we 
performed GO enrichment analysis to determine whether proteins showing full-length 
specific biotinylation where known to be involved with these and other novel biological 
pathways and processes (Figure 4.5A). Survey of biological processes and KEGG 
pathways revealed an enrichment of proteins mapping to pathways associated with either 
endocytosis (CLINT1, CLTC, CTTN, GAK, HIP1, HSP90AA1, HSPA8), receptor 
tyrosine kinase signaling (GIGYF2, HGS, HSP90AA1, STAM2, STAT3), or both (CRK, 
EPS15L1, NCK1, TNK2) (Figure 4.5A). Next, we sought to determine whether there was 
a prevalence of known protein-protein interactions between the full-length TNK2-specific 
biotinylation proteins identified in our dataset. To identify such interactions, we performed  
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Figure 4.5. Pathway enrichment and STRING analysis of protein significantly 
biotinylated in cells expressing TNK2 FL-BirA* construct. (A) Results from Gene 
Ontology (GO) enrichment analysis of biotinylated proteins that displayed a ≥2-fold higher 
abundance in cells expressing full-length relative to truncated protein (n = 40). Top five 
biological processes and KEGG pathways found to be significantly enriched (p < 0.05) are 
shown. Dashed line denotes p-value threshold for 0.05. (B) Results from STRING analysis 
of biotinylated proteins that displayed a ≥2-fold higher abundance in cells expressing full-
length relative to truncated protein. The image was created using Cytoscape. The node size 
is proportional to the protein level fold-change (FL-BirA* vs. ΔC-BirA*) for each 
biotinylated protein, with the smallest circle corresponding to a 2-fold change and the 
largest circle corresponding to a 20-fold change. Known interactors or phosphorylation 
substrates of TNK2 based on database and literature searches are labeled in red. (C) Top 
scoring cluster from the protein interaction network shown in (B). Identification and 
analysis of enriched sub-clusters was conducted using the MCODE clustering algorithm.   
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STRING analysis, which revealed the presence of experimental verified protein-protein 
interactions amongst the proteins found to show significant biotinylation in full-length 
TNK2 (Figure 4.5B). Within the resulting protein interaction network, we were able to 
identify several functional clusters or interaction modules, potentially indicating proximal 
protein complexes. Members of the top scoring cluster (Figure 4.5C) included already 
known TNK2 interactors, including CTTN, CLTC, and GAK, as well as several novel 
interaction candidates, such as AGFG1, CLINT1, HIP1, HSP8, OCRL, and VAMP2. This 
sub-cluster accounted for a majority of the proteins that were found in our GO enrichment 
analysis to be associated with endocytosis and related processes, indicating a potential 
protein complex that may be involved in carrying out TNK2-mediated endocytosis. We 
were able to validate interaction between TNK2 and a member of this sub-cluster, Clathrin 
interactor 1 (CLINT1), by performing immunoblot analysis on proteins that co-
immunoprecipitated (co-IP) from an anti-HA tag pulldown (Figure 4.6B). CLINT1 was 
observed only in eluates obtained from anti-HA tag IP from lysates of cells expressing 
TNK2 FL-BirA*, suggesting this interaction required the full-length TNK2 protein. As a 
positive control, we performed a parallel co-IP for confirming interaction between full-
length TNK2 and NCK1, a well-established binding partner for TNK2 (Figure 4.6A). 
Therefore, our analysis demonstrates that a differential interactome study using a SILAC-
BioSITe approach can enable the detection and identification of true novel interactors of a 
protein of interest. 
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Figure 4.6. Validation of CLINT1 interaction with full-length TNK2-BirA* using co-
immunoprecipitation analysis. (A) Western blot analysis of control mouse IgG and anti-
HA tag IP from cells expressing TNK2 FL-BirA* or ΔC-BirA*. Western blot analysis was 
performed using antibodies against NCK adaptor protein 1 (NCK1) and HA-tag. Analysis 
of whole cell lysates with anti-NCK1 was performed in parallel. (B) Western blot analysis 
of control mouse IgG and anti-HA tag IP from cells expressing TNK2 FL-BirA* or ΔC-
BirA*. Western blot analysis was performed using antibodies against Clathrin interactor 1 






 Large-scale interaction studies employing high-throughput platforms have become 
increasing popular for obtaining “comprehensive” protein-protein interactome maps of 
protein families (122) and even entire human interactomes (123,124). However, there is a 
need for appropriate controls or complementary methods that help pinpoint true interactors 
among the large list of candidates rendered from one method alone. BioID and other 
proximity based labeling strategies can serve as good complementary methods to assist in 
the prioritization and sorting of high confidence protein interactors. In fact, large scale 
studies based on proximity dependent biotinylation are already becoming popular for 
mapping interactomes for protein families, including G protein coupled receptors 
(125,126), protein phosphatases (127), nuclear transport receptors (128), as well as for 
individual proteins like paxillin (129), fibroblast growth factor receptors (FGFRs) 
(130,131), transcription factor SOX2 (132), dynein (133), and many others. However, these 
methods are not being applied for studying molecules whose protein interactomes have not 
yet been comprehensively characterized. In the present work, we described how we 
mapped the interactome of one of the few understudied but important kinases: non-receptor 
tyrosine kinase 2 (TNK2). TNK2 has an established role in driving various cancers, and 
we also recently identified it as one of the proteins that exhibits increased tyrosine 
hyperphosphorylation downstream of two different oncogenic KRAS mutations. We show 
the coupled use of BioID with BioSITe, which allowed us to obtain site-level biotinylation 
evidence for putative TNK2 binders. Furthermore, we show how to use this strategy for a 
quantitative proteomics experiment employing SILAC to compare the relative abundance 
of biotinylated proteins between full-length and truncated version of TNK2. This approach 
allowed us to recapitulate known interactors of TNK2, but also identify several novel TNK2 
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interactors, including clathrin interactor 1 (CLINT1). Further experiments are warranted to 
assess the functional significance of novel TNK2 interactors in TNK2-mediated signaling. 
We believe that the strategy used in this work is broadly applicable for the field of protein 
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